Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
作者信息
Soumerai Jacob D, Rosenthal Allison, Harkins Shannon, Duffy Jessica, Mecca Carmen, Wang Yingbing, Grewal Ravinder K, El-Jawahri Areej R, Liu Huiyun, Menard Cedric, Dogan Ahmet, Yang Lei, Rimsza Lisa M, Bantilan Kurt, Martin Haley, Lei Matthew, Mohr Sydney, Kurilovich Anna, Kudryashova Olga, Postovalova Ekaterina, Nardi Valentina, Abramson Jeremy S, Chiarle Roberto, Zelenetz Andrew D, Louissaint Abner
机构信息
Massachusetts General Hospital Cancer Center, Boston, MA.
Mayo Clinic, Scottsdale, AZ.
出版信息
Blood. 2022 Oct 20;140(16):1822-1826. doi: 10.1182/blood.2022015443.
Abstract
摘要
相似文献
1
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.下一代ALK抑制剂在ALK阳性大B细胞淋巴瘤中具有高度活性。
Blood. 2022 Oct 20;140(16):1822-1826. doi: 10.1182/blood.2022015443.
2
Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor).间变性淋巴瘤激酶（ALK）阳性肺神经内分泌肿瘤对阿来替尼（ALK抑制剂）反应良好
Clin Lung Cancer. 2023 May;24(3):e113-e116. doi: 10.1016/j.cllc.2022.12.004. Epub 2022 Dec 26.
3
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.布加替尼与其他第二代间变性淋巴瘤激酶抑制剂作为深度表型分析的间变性淋巴瘤激酶阳性非小细胞肺癌的初始治疗比较：ABP 试验研究方案。
BMC Cancer. 2021 Jun 28;21(1):743. doi: 10.1186/s12885-021-08460-w.
4
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).间变性淋巴瘤激酶（ALK）在非小细胞肺癌（NSCLC）中的作用和治疗靶点。
Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4.
5
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
6
Research Progress on the Drug Resistance of ALK Kinase Inhibitors.ALK激酶抑制剂的耐药性研究进展
Curr Med Chem. 2022;29(14):2456-2475. doi: 10.2174/0929867328666210806120347.
7
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.针对晚期非小细胞肺癌中间变性淋巴瘤激酶酪氨酸激酶抑制剂的耐药谱：一项使用靶向下一代测序的多中心研究。
Eur J Cancer. 2021 Oct;156:1-11. doi: 10.1016/j.ejca.2021.06.043. Epub 2021 Aug 13.
8
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.阿来替尼在间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗中的应用。
Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14.
9
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.ALK 化合物突变（I1171S + G1269A）克服对多种 ALK 抑制剂的序贯治疗后在非小细胞肺癌中的耐药性。
Thorac Cancer. 2020 Mar;11(3):581-587. doi: 10.1111/1759-7714.13299. Epub 2020 Jan 13.
10
Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma.间变性淋巴瘤激酶阳性大B细胞淋巴瘤原发性难治性患者使用间变性淋巴瘤激酶抑制剂的持久反应。
Blood Adv. 2023 Jun 27;7(12):2912-2916. doi: 10.1182/bloodadvances.2022007537.
引用本文的文献
1
Comparative DNA Methylation Profiling of Human and Murine ALK-Positive B-Cell Neoplasms.人类和小鼠ALK阳性B细胞肿瘤的DNA甲基化谱比较分析
Genes Chromosomes Cancer. 2025 Jul;64(7):e70060. doi: 10.1002/gcc.70060.
2
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
3
Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review.阿来替尼联合VRCD和BV单克隆抗体治疗ALK阳性大B细胞淋巴瘤：1例病例报告及文献复习
Front Oncol. 2025 Jan 21;14:1480880. doi: 10.3389/fonc.2024.1480880. eCollection 2024.
4
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.间变性淋巴瘤激酶（ALK）抑制剂增强了CD47阻断在敏感和耐药的ALK驱动恶性肿瘤中诱导的吞噬作用。
Biomedicines. 2024 Dec 12;12(12):2819. doi: 10.3390/biomedicines12122819.
5
Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.淋巴细胞恶性细胞转化的多样且可重编程机制：发病机制见解与转化意义。
Front Oncol. 2024 Apr 3;14:1383741. doi: 10.3389/fonc.2024.1383741. eCollection 2024.
6
Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives.后颅窝肿瘤中的间变性淋巴瘤激酶（ALK）：诊断、预后及治疗前景的范围综述
Cancers (Basel). 2024 Feb 2;16(3):650. doi: 10.3390/cancers16030650.
7
fusion in ALK positive large B-cell lymphoma: a case report and review of literature.ALK阳性大B细胞淋巴瘤中的融合：一例病例报告及文献复习
Front Oncol. 2023 May 25;13:1174606. doi: 10.3389/fonc.2023.1174606. eCollection 2023.
8
Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma.间变性淋巴瘤激酶阳性大B细胞淋巴瘤原发性难治性患者使用间变性淋巴瘤激酶抑制剂的持久反应。
Blood Adv. 2023 Jun 27;7(12):2912-2916. doi: 10.1182/bloodadvances.2022007537.
本文引用的文献
1
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.酪氨酸磷酸酶调节 ALK+间变大细胞淋巴瘤对 ALK 抑制剂的耐药性。
Blood. 2022 Feb 3;139(5):717-731. doi: 10.1182/blood.2020008136.
2
First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer.一线劳拉替尼或克唑替尼治疗晚期阳性肺癌。
N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187.
3
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.IL10RA 调节 NPM1-ALK+ 间变大细胞淋巴瘤对克唑替尼的敏感性。
Blood. 2020 Oct 1;136(14):1657-1669. doi: 10.1182/blood.2019003793.
4
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Wiskott-Aldrich 综合征蛋白（WASP）是 T 细胞淋巴瘤中的一种肿瘤抑制因子。
Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.
5
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.洛拉替尼治疗在 ALK 驱动的癌症中引发多种靶内和靶外耐药机制。
Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15.
6
Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.在ALK阳性大B细胞淋巴瘤中鉴定出一种新型GORASP2-ALK融合基因。
Leuk Lymphoma. 2019 Feb;60(2):493-497. doi: 10.1080/10428194.2018.1493731. Epub 2018 Sep 6.
7
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
8
ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature.ALK阳性大B细胞淋巴瘤：26例临床病理研究并复习文献中另外108例病例
Am J Surg Pathol. 2017 Jan;41(1):25-38. doi: 10.1097/PAS.0000000000000753.
9
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.阿来替尼用于ALK阳性、克唑替尼耐药的非小细胞肺癌：一项单组、多中心、2期试验。
Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19.
10
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
Zotero 插件